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Summary The recently identified Fanconi anaemia A (FAA) gene is located on chromosomal band 16q24.3 within a region that has been
frequently reported to show loss of heterozygosity (LOH) in breast cancer. FAA mutation analysis of 19 breast tumours with specific LOH at
16q24.3 was performed. Single-stranded conformational polymorphism (SSCP) analysis on cDNA and genomic DNA, and Southern blotting
failed to identify any tumour-specific mutations. Five polymorphisms were identified, but frequencies of occurrence did not deviate from those
in a normal control population. Therefore, the FAA gene is not the gene targeted by LOH at 16q24.3 in breast cancer. Another tumour
suppressor gene in this chromosomal region remains to be identified.
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Article no. bjoc.1998.0168Tumour suppressor genes are characterized by mutational inacti-
vation of both alleles in tumour DNA. In general, one copy is
inactivated by a small mutation, i.e. a point mutation or frameshift,
whereas the other copy is lost by large genomic deletions or
mitotic recombination, reflected in loss of heterozygosity (LOH)
of adjacent polymorphic markers. LOH on the long arm of
chromosome 16 has been detected frequently in breast tumours
(Cleton-Jansen et al, 1994; Tsuda et al, 1994; Dorion-Bonnet et al,
1995; Skirnisdottir et al, 1995; Iida et al, 1997), and also other
tumours, especially prostate cancer (Cher et al, 1995; Suzuki et al,
1996; Latil et al, 1997). Detailed deletion mapping has shown that
several regions on chromosome arm 16q are targets for LOH, one
of which is located near the telomere at 16q24.3. This region is
bordered by markers APRT and D16S303.
A strong candidate gene located within this region is the
Fanconi Anaemia group A (FAA) gene, which was recently
identified (Pronk et al, 1995; Fanconi Anemia/Breast Cancer
Consortium, 1996; Lo Ten Foe et al, 1996). FAA encodes a protein
of 1455 amino acids and has no significant homology to any other
protein. Fanconi anaemia (FA) is an autosomal recessive genetic
disorder characterized by progressive pancytopenia and congenital
malformations. Since FA patients have a high predisposition to
develop malignancies, and their cells show chromosomal insta-
bility and increased sensitivity to bifunctional alkylating agents in
vitro, we postulated that the FAA gene could be the gene targeted
by LOH on 16q24.3.Received 30 January 1998
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Correspondence to: A-M Cleton-Jansen, Department of Pathology,
Leiden University Medical Center, PO Box 9600, NL-2300 RC Leiden,
The NetherlandsThis report describes a mutation analysis of the retained copy of
the FAA gene in breast tumours with LOH only at 16q24.3. This
specific set of tumours ensures that the gene at 16q24.3 is the
target for LOH and not another gene on chromosome 16q, e.g. a
gene at 16q22.1, a region also implicated in LOH.
MATERIALS AND METHODS
Tumour material
Freshly frozen breast tumour tissue was collected at the
Department of Pathology of the Leiden University Medical
Center. Haematoxylin and eosin-stained sections of tumour tissue
blocks were examined by a pathologist to select cases that
contained at least 50% tumour cells. Tumours for FAA mutation
analysis were selected by testing polymorphic markers on chromo-
some 16 as has been described previously (Cleton-Jansen et al,
1994). Seventeen tumours showing LOH only on chromosomal
band 16q24.3, two tumours showing complex LOH on 16q22 and
16q24.3 but retention of markers in between and three controls
without 16q LOH were used in this study. The LOH pattern on 16q
of the tumours was shown by dense LOH mapping, which was
described in detail by Moerland et al (1997). Genomic DNA from
50 healthy controls originating from the Dutch population was
used for testing frequencies of polymorphisms.
Mutation screening
RNA was extracted from 10Ð20 sections of 20 m m from tumour
tissue blocks using TRIzol reagent (GIBCO BRL) according to the
manufacturerÕs instructions. cDNA was synthesized from 1 to
10 m g RNA in a 20 m l reaction volume containing 0.2 units AMV
reverse transcriptase (RT; Boehringer), 1 m g random primed
hexamers, 2 mM dNTP in the buffer supplied with the enzyme.1049
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Table 1 SSCP analysis of FAA on breast tumour cDNA
cDNA FAA1 FAA2 FAA3 FAA4 FAA5 FAA6 FAA7 FAA8
fragment –7–400 335–719 656–1368 1323–1684 1625–2011 1924–2558 2017–2826 2783–4408
exon 1–4 4–7 8–14 15–18 18–22 22–27 23–29 29–43
Tumours with LOH only on 16q24
BT309 Nb N 796AGc 1501AG N 2426AA
BT358 Ga d 796AG 1501AG
BT367 N 796AG 1501AG N 2426AG
BT378 N N N
BT408 N 796GG 1501AG N 2426AA
BT410 N N 796AA 1501AG N 2426GG
BT413 N N 796AG 1501AG 2426AA N N
BT465 796AA 1501GG 2426AG
BT470 N N 796AA 1501GG 2426AG
BT541 G N N 796AG 1501AG N 2426GG N N
BT559 G N N 796AG 1501AG N 2426AG N N
BT589 G N N 796GG 1501GG 2426AA
BT666 G 796AG 1501AG N 2426GG
BT757 G N 796AG 1501AA N 2426AA
BT819 N N 796AA 1501GG N 2426GG N N
BT912 N N 796AA 1501GG
BT919 G N 796GG 1501AG 2426AA N N
Tumours with complex LOH only on
16q24 and 16q22
BT355 N N 796GG 1501GG N 2426GG N N
BT555 G N 796GG 1501AG N 2426GG N N
Tumours with retention on chromosome 16q
BT335 1501AG 2426AA
BT655 N 796GG 1501GG 2426GG
BT805 N N 796GG 1501AG N 2426AA
aG indicates that this sample was also analysed in a genomic DNA based exon-by-exon SSCP. bN indicates that the sample was tested, but no variant bands
were found. cNumbers refer to the position of a variant nucleotide in the cDNA sequence (1 = first basepair of the FAA start codon); letters indicate which alleles
are identified in the sample.dEmpty cells: sample not tested for this fragment.Polymerase chain reaction (PCR) reactions were performed on
2 m l cDNA with primers derived from the FAA cDNA sequence.
Table 1 shows the PCR strategy. Primer sequences and PCR condi-
tions are available on request. PCR fragments FAA1 to FAA6 were
radiolabeled by the addition of 2 m Ci a -32P-dCTP and digested
with restriction enzymes resulting in fragments of appropriate
length to be analysed by single-strand conformational poly-
morphism (SSCP). FAA7 and FAA8 were amplified in a first step,
followed by a nested PCR, which resulted in 3 and 6 radiolabelled
fragments, respectively, with a size range between 200 and 400 bp.
RT-PCR products were analysed on SSCP gels containing 10%
glycerol, 6% acrylamide and TBE or MDE gels (Boehringer). If a
variant band pattern was observed in an RT-PCR fragment,
sequencing was performed using a Cycle Sequencing kit (Perkin
Elmer). Subsequently, restriction enzyme analysis on PCR pro-
ducts amplified from genomic DNA of tumour and normal tissue
of all patients and on DNA from healthy controls was applied to
determine the frequency of the variant alleles (Table 2).
Genomic DNA from eight tumours was also tested in an exon-
by-exon SSCP analysis described elsewhere (Wijker et al, 1998).
The 43 exons of FAA (Lanzano et al, 1997) were amplified from
genomic DNA with primers located 40Ð60 bp from the exon
boundaries with T7 (sense) and Sp6 (antisense) sequences to facil-
itate sequencing. Fragments were analysed by SSCP on a 20%
acrylamide gel with silver staining to visualize the bands. Southern
analysis to identify genomic rearrangements or large deletions was
performed as described previously (Devilee et al, 1991).British Journal of Cancer (1999) 79(7/8), 1049–1052RESULTS
Table 1 shows the results of the SSCP analysis on cDNA of the
tumours. No tumour-specific variations were found, either in
cDNA or genomic DNA. SSCP analysis sometimes resulted in
altered banding patterns. Upon sequencing of the PCR fragments
showing variations, these always appeared to be polymorphisms
of the FAA gene that could also be identified in a normal control
population. Moreover, analysis of DNA from non-neoplastic cells
of the same patient showed that these variants were also present in
the germline and were, therefore, not tumour-specific. Both alleles
of a polymorphism could be recognized in DNA from tumour
tissue, due to a 20Ð50% contamination with non-neoplastic cells.
Table 2 shows these polymorphisms, their location, nature, result
on the amino acid sequence, and occurrence in breast tumours and
in controls. Although all four polymorphisms resulted in an amino
acid change, none of these appeared to be more predominant in
patients with breast cancer and cannot, therefore, be considered as
pathogenic germline mutations. An exception is the 17T/A (V/D6)
variant, which was found in only 1 out of 100 chromosomes of the
control population but in 2 out of 16 chromosomes in patients.
However, in one patient, case BT555, there was LOH of the 17T
allele, whereas in the other, case BT757, the 17A allele showed
LOH, indicating that there is no preferential LOH for one allele or
the other. This polymorphism was also identified in a Fanconi
anaemia A family, but did not segregate with the disease pheno-
type (Levran et al, 1997). The V/D6 variant was only detected by© Cancer Research Campaign 1999
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Table 2 Polymorphisms detected in FAA in breast tumour samples
Location Exon Variation AA % in breast % in Restriction
change cancera controlsa enzymeb
17 1 T/A V/D6 12% [16] 1% [100] Destroys Drdl
796 9 A/G T/A266 47% [34] 50% [50] Creates BstUl
1501 16 G/A G/S501 65% [38] 65% [94] Destroys Mspl
2426 26 G/A G/D809 50% [38] 46% [60] Destroys Dralll
a% of variant allele; between brackets: number of chromosomes tested. bRestriction enzyme analysis for detection of the polymorphism in PCR fragments on
genomic DNA.SSCP analysis on genomic DNA, not on cDNA, most probably
because the PCR primer for the genomic assay was located 50 bp
upstream of the start codon, and the cDNA primer was only 7 bp
upstream.
Evidence for large genomic deletions in FA patients has been
reported (Fanconi Anemia/Breast Cancer Consortium, 1996).
Since large deletions and other rearrangements cannot be detected
by PCR a subset of seven tumours with LOH at 16q24.3, six breast
tumour cell lines and two normal mammary epithelial cell lines,
were examined by Southern analysis. DNA from breast tumour
cell lines was obtained from CAMA-1, MCF7, MDA468, BT474,
ZR75-1 and MPE600 (kindly provided by Dr Joe Gray), and from
SV40 transformed mammary epithelial cell lines HBL100 and
RC6. Four of these breast tumour cell lines show homozygosity
for four highly polymorphic markers near the FAA gene,
suggesting that LOH had occurred at 16q24. DNA was digested
with MspI, TaqIor PvvuII, blotted onto Hybond N+ membranes
and hybridized with an FAA full-length cDNA probe (provided by
Dr Hans Joenje). None of the tumour samples or cell lines showed
aberrant bands. The FAA cDNA recognized a variant band of
3.4 kb in Pvull digests of two out of seven tumours tested, but this
was also present in non-neoplastic DNA and is, therefore, consid-
ered to be a polymorphism. Southern analysis of DNA from 11
healthy controls showed that this polymorphism could be found in
two individuals, a frequency similar to that in patients.
DISCUSSION
The most distal region of chromosome arm 16q has been
frequently implicated as a target for LOH in both breast cancer and
prostate cancer and is, therefore, likely to contain a tumour
suppressor gene. LOH studies of this chromosome arm in breast
tumours have also implicated other candidate regions. The E-
cadherin gene located at 16q22.1 was actually shown to be the
target of LOH, i.e. one copy was affected by a protein truncating
mutation and the other copy removed by LOH (Berx et al, 1995,
1996). The E-cadherin gene, however, is only targeted in lobular
breast tumours, which comprise a minority of 5Ð10% of the total
number of cases.
The Fanconi anaemia A susceptibility gene is located at 16q24.3
(Pronk et al, 1995; Gschwend et al, 1996) in the smallest region of
overlap that was defined by detailed deletion mapping of 79 breast
tumours (Cleton-Jansen et al, 1994). FAA encodes a unique protein
that does not exhibit any homology to known proteins that might
suggest a function. Recently, it was suggested that FA is due to a
defective caretaker gene, as are ataxia-telangiectasia, Bloom© Cancer Research Campaign 1999syndrome, hereditary non-polyposis colorectal cancer, Werner
syndrome and the nucleotide excision repair syndromes xeroderma
pigmentosum, Cockayne syndrome and trichothiodystrophy
(Levran et al, 1997). Each of these genes is responsible in a unique
way for the integrity of the genome, and when mutated causes
predisposition to cancer. FA patients are known to be at high risk
for malignancy (Alter, 1996), while the cancer risk in FA carriers
has not been well studied as yet. Cultured FA cells show baseline
chromosomal instability as well as increased levels of chromo-
somal aberrations induced by DNA cross-linking agents. Since
tumour cells are characterized by chromosomal instability, FAA
was postulated to be a candidate for the gene targeted by LOH of
this region. In addition, the breast tumour suppressor genes
BRCA1 and BRCA2 were shown to play a role in DNA repair
(Scully et al, 1997; Patel et al, 1998).
This report shows that, although a specific set of 19 breast
tumours with isolated LOH of 16q24.3 was screened for mutations
in the FAA gene using three different approaches, SSCP on cDNA,
SSCP on genomic DNA and Southern analysis, no tumour-specific
mutations were found. The SSCP analysis on genomic DNA was
identical to that used in a study on FA patients (Wijker et al, 1998).
This study shows that the method is able to identify mutations and
polymorphisms. Moreover, our analysis is corroborated by the
identification of naturally occurring polymorphisms in the FAA
coding sequencing. The high number of polymorphisms found is
in concordance with the recently reported variability of the FAA
gene (Levran et al, 1997).
The FAA gene is rich in Alu sequences (Ianzano et al, 1997)
suggesting Alu-mediated recombination resulting in large genomic
deletions might be an important mechanism for the generation of
FAA mutations. Several such genomic deletions, which would be
missed by SSCP analysis, have been observed in FA patients
(Fanconi Anemia/Breast Cancer Consortium, 1996; Centra et al,
submitted; Levran et al, submitted). Therefore, a subset of seven
tumours and six breast tumour cell lines was tested by Southern
analysis to identify large genomic rearrangements, but this did not
result in the identification of such mutations in breast tumours.
In conclusion, the FAA gene has been excluded as the breast
tumour suppressor gene on 16q24.3 targeted by LOH. Therefore,
another gene in this region remains to be identified.
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